Shopping Cart
MEET THE TEAM

Leadership

Our management team has extensive experience in the life science and technology sectors, including scientific, technical and operational expertise. We are focused on meeting the significant unmet needs of the research and clinical markets through technological innovation and superior customer service.

Board of Directors

Wenbin Jiang Ph.D.
Cytek Biosciences, CEO
keyboard_arrow_down

Dr. Jiang is a prolific inventor and a co-founder of Cytek Biosciences. As the CEO and Chairman of the Board, Dr. Jiang has led the company through four rounds of financing for a total of $200M raised, grown the company to multi-continents and achieved an average growth rate exceeding 100% over the life of the company.

Prior to Cytek Biosciences, Dr. Jiang served as CTO at Cosemi Technologies Inc. and JDSU Transmission Module BU. He received a PhD in Electrical Engineering from the University of California, Santa Barbara, a MS in Optics and a BS in Physics from Fudan University in Shanghai, China.

Over his career, he has contributed to 100 US patents, published more than 50 peer reviewed journal and conference papers, and wrote 5 book chapters. He has been awarded the Motorola Master Innovator Award and JDSU Inventor of the Year.

Jack Ball
Solulink Inc., CEO
keyboard_arrow_down

Jack Ball has served as a member of our board of directors since September 2018. Mr. Ball also serves as the President of Tyball Associates LLC and serves on the board of directors of Carterra, Inc., a biotechnology company, NanoCellect Biomedical, Inc., a biotechnology company.

From October 2010 to March 2021, Mr. Ball served on the board of directors of Swift Biosciences Inc., a biotechnology company. From September 2013 to December 2019, Mr. Ball served as Chief Executive Officer and a board member at Solulink Inc., a biotechnology company. From February 2006 to July 2011, Mr. Ball was Chief Commercial Officer at Accuri Cytometers, Inc., a medical instruments company, which was sold to Becton Dickinson & Co in March 2011. Prior to that, Mr. Ball was Chief Executive Officer at Amnis Corporation, a biotechnology company, Chief Commercial Officer at Molecular Probes, Inc., a biotechnology company, Senior Vice President and General Manager at Orchid Biosciences, a DNA testing services biotechnology company and President for North America at Amersham Biosciences Corp., a healthcare company. Mr. Ball holds a B.S. in Agriculture from the University of Georgia.

Ming Yan Ph.D.
Cytek Biosciences, CTO
keyboard_arrow_down

Dr. Yan is a co-founder of Cytek Biosciences with over 25 years of R&D experience in leadership and innovation. As CTO of Cytek, Ming leads the development team (including hardware, software, reagents, and applications), and with the team, drives the advancement of the Cytek Platform.

Prior to Cytek, Ming worked in the biomedical instruments industry and integrated photonics at AT&T Bell laboratories, Livermore national laboratories, Neophotonics and BD Biosciences. Ming is one of the thought-leaders in flow cytometry instrumentation and standardization. He received his Ph.D in Electrical Engineering and MS in Physics from City University of New York, BS in Physics from Fudan University.

Dr. Yan has published over 40 research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and patent pending applications for his innovations.

Feng Deng
Northern Light Venture Capital
keyboard_arrow_down

Feng Deng has served as a member of our board of directors since August 2018. Mr. Deng founded Northern Light Venture Capital in 2005. Mr. Deng also serves as a member of the board of directors of Burning Rock Biotech Limited, a biotechnology company. Prior to Northern Light Venture Capital, he was a co-founder of NetScreen Technologies, a network security company, which went public on NASDAQ and was later acquired by Juniper Networks, a network equipment manufacturing company in 2004.

Mr. Deng has extensive technical and managerial experiences in computer, communication and data networking industries and holds numerous 149 patents of invention in computer system architecture and integrated circuit design. Mr. Deng holds a B.S. and M.S. in electrical engineering from Tsinghua University, an M.S. in computer engineering from the University of Southern California and an M.B.A. from the Wharton School, University of Pennsylvania.

Gisele Dion
Independent Advisor
keyboard_arrow_down

Gisele Dion has served as a member of our board of directors since March 2021. Ms. Dion was the Senior Advisor to the Chief Financial Officer of Takeda Pharmaceutical Ltd., a pharmaceutical company from March 2021 to June 2021. Prior to that, she served as the Senior Vice President, Chief Accounting Officer and Corporate Controller at Takeda Pharmaceutical Ltd. from January 2019 to March 2021. Prior to that, Ms. Dion was the Senior Vice President, Chief Accounting Officer and Corporate Controller at Shire Pharmaceuticals LLC, a biopharmaceutical company, from January 2016 to January 2019. From 2007 to January 2016, she served as Corporate Controller and Senior Director of Technical Accounting of Biogen Inc., a biotechnology company.

Ms. Dion received a B.S. in Accounting and Management Information Systems from Fairfield University. We believe that Ms. Dion’s extensive experience in finance and accounting provides her with the qualifications and skills to serve as a director of our company.

Tess Cameron
RA Capital Management
keyboard_arrow_down

Tess Cameron has served as a member of our board of directors since April 2021. Ms. Cameron is the Principal, Strategic Finance at RA Capital Management, LP. From January 2018 to June 2020, Ms. Cameron served as the Head of Finance of Foghorn Therapeutics, Inc., a pharmaceutical company. From January 2017 to January 2018, Ms. Cameron served as the Director, Financial and Business Planning at WAVE Life Sciences Ltd., a biotechnology company.

Prior to that Ms. Cameron was the Associate Director, Finance Business Planning and Senior Finance Manager at Biogen Inc., a biotechnology company and worked at McKinsey & Company, a management consulting company. Ms. Cameron holds a B.A. in Economics and Peace Conflict Studies from Victoria University, University of Toronto and graduated from the Mini-MBA program at the Tuck School of Business, Dartmouth College.

Scientific Advisory Board

Diether J. Recktenwald Ph.D.
Principal at Desatoya LLC
Bob Hoffman
Consultant in Flow Cytometry and Biophotonics
Holden Maecker Ph.D.
Professor of Microbiology and Immunology at Stanford University
Dr. rer. nat. Andreas Radbruch
Professor at Deutsches Rheuma-Forschungszentrum – Berlin, Germany
Frederic I. Preffer, Ph.D.
Professor of Pathology/ Harvard Medical School
Editor-in-Chief, Clinical Cytometry
Director, Immunopathology /Warren 5
Department of Pathology /Massachusetts General Hospital